Thermo Fisher Scientific Unveils Next-generation Innovations to Advance Drug Discovery
Advertisement
By combining high-performance instrumentation with AI-enabled software for scalable multiomics and biopharmaceutical solutions, the platform is expected to advance drug discovery
Global medtech company Thermo Fisher Scientific has announced the launch of the next-generation Thermo Scientific OrbitrapTribrid Apex and Thermo Scientific Orbitrap Excedion mass spectrometers, designed to support drug discovery, translational research, and clinical laboratory applications.
The latest device was announced at a recent event and aims to support the researchers and drug developers in managing complex discovery and generating high-quality data.
By combining high-performance instrumentation with AI-enabled software for scalable multiomics and biopharmaceutical solutions, the platform is expected to advance drug discovery and development.
The latest capabilities are designed to help researchers identify and validate disease mechanisms more efficiently while advancing targeted treatments.
Thermo Fisher Scientific, the Orbitrap Tribrid Apex system is built on the proven Thermo Scientific Orbitrap Tribrid Technology and is designed to enable researchers to study complex biology across multiomics, structural biology, biopharma characterisation, and small-molecule analysis on a single system.
As per the company, the system is intended to support the analysis of complex biological samples with improved sensitivity, broader sequence coverage, and faster processing compared to earlier-generation systems.
The platform is designed to support researchers in identifying therapeutic targets sooner across conditions like cancer and neurodegeneration, as well as help translate these discoveries into faster progress across drug discovery and development.
In addition, the Thermo Scientific Orbitrap Excedion Mass Spectrometer is designed to help pharmaceutical scientists reduce risk in increasingly complex drug development pipelines, including GLP-1 therapies, oligonucleotides, and antibody-drug conjugates.
As per Thermo Fisher Scientific, the system is designed to support the detection and analysis of compounds in complex samples and generate data for safety, efficacy, and dosing-related studies in regulated research environments.
The platform also seeks to enable the identification of low-abundance molecules and other critical molecular signals during early-stage analysis while helping reduce downstream risk, improve regulatory readiness, and accelerate time to market.
Speaking on the new initiative, Marc N. Casper, Chairman and Chief Executive Officer of Thermo Fisher Scientific, said, “By combining next-generation Orbitrap platforms with AI-driven analytics, we are now helping scientists transform increasingly complex data into actionable insights to further accelerate the path from discovery to precision therapies.”
Reportedly, the company is also set to unveil the Olink proteomics platform, which enables high-specificity protein analysis at a population scale and complements Orbitrap-based discovery workflows.
This combined approach is already being applied in initiatives such as PRECISE, one of Asia’s most ambitious and diverse biobank programs to uncover biomarkers linked to ageing and metabolic disease.
Stay tuned for more such updates on Digital Health News
